Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Amylyx’s ALS Pledge Vs. FDA’s Obscure Withdrawal Authority: Which Holds More Power?
Sep 17 2022
•
By
Sue Sutter
Pulling a drug off the market may be more challenging that getting the horses back in the barn. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers